Heparin

selectin P ; Homo sapiens







62 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32452079 Quantification of heparin's antimetastatic effect by single-cell force spectroscopy. 2021 Jan 4
2 33805059 A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. 2021 Mar 24 1
3 33806140 Functional Flow Cytometric Assay for Reliable and Convenient Heparin-Induced Thrombocytopenia Diagnosis in Daily Practice. 2021 Mar 25 1
4 34261860 P-selectin expression assay in a repeatedly serotonin-release assay-negative patient with heparin-induced thrombocytopenia. 2021 Oct 1 1
5 32110917 Glycosaminoglycans as Tools to Decipher the Platelet Tumor Cell Interaction: A Focus on P-Selectin. 2020 Feb 26 1
6 32733248 Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease. 2020 1
7 31212795 Tunicate Heparan Sulfate Enriched in 2-Sulfated β-Glucuronic Acid: Structure, Anticoagulant Activity, and Inhibitory Effect on the Binding of Human Colon Adenocarcinoma Cells to Immobilized P-Selectin. 2019 Jun 12 1
8 27759896 Platelet activation in the presence of neutral protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes. 2017 Jan 2
9 25367817 Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: Effect on P-selectin, heparanase, metastasis and cellular recruitment. 2015 Apr 3
10 26349809 Analytical cell adhesion chromatography reveals impaired persistence of metastatic cell rolling adhesion to P-selectin. 2015 Oct 15 1
11 22194593 Heparin-induced leukocytosis requires 6-O-sulfation and is caused by blockade of selectin- and CXCL12 protein-mediated leukocyte trafficking in mice. 2012 Feb 17 2
12 22488107 A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. 2012 May 1
13 22862794 Simultaneous assay of activated platelet count and platelet-activating capacity by P-selectin detection using K2-EDTA-treated whole blood for antiplatelet agents. 2012 Dec 1
14 21648090 The role of dimension in multivalent binding events: structure-activity relationship of dendritic polyglycerol sulfate binding to L-selectin in correlation with size and surface charge density. 2011 Aug 11 1
15 21793788 RNA aptamer therapy for vaso-occlusion in sickle cell disease. 2011 Aug 1
16 20970300 Study on anti-metastasis of heparin derivatives as ligand antagonist of p-selectin. 2010 Dec 4
17 19026722 Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. 2009 Feb 1
18 19929245 Thrombin-inducible platelet adhesion and regulation of the platelet seven-transmembrane thrombin receptor-1 (PAR-1): effects of unfractionated heparin and lepirudin. 2009 Dec 1
19 21475829 Inhibitory effects of chemically modified heparin on the P-selectin-mediated adhesion of breast cancer cells in vitro. 2009 Mar-Apr 5
20 18451252 Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis. 2008 May 1 1
21 18940719 Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain. 2008 Oct 1
22 17393024 Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. 2007 Apr 1
23 17458940 Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition. 2007 May 22 4
24 16139336 Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. 2006 3
25 16331491 Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. 2006 Apr 4
26 16525583 The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. 2006 Mar 4
27 16709700 Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. 2006 Nov 2
28 16780802 The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. 2006 Aug 14 1
29 16157224 Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. 2005 Nov 8 6
30 15133030 Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. 2004 Jul 9 7
31 15201252 Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. 2004 Jul 1
32 15217633 P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment. 2004 Jul 3
33 23570202 The relationship between thrombin and platelets: linking vessel injury to thrombosis and inflammation. 2004 Dec 2
34 12626998 Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. 2003 Mar 2
35 12682480 Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. 2003 Apr 1
36 12888879 Affinity and kinetics of P-selectin binding to heparin. 2003 Aug 6
37 11854515 Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. 2002 Feb 19 1
38 11885026 Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. 2002 Feb 2
39 12355033 Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. 2002 Jun 2
40 12393591 Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. 2002 Nov 15 3
41 12487777 Influence of heparin coating of coronary stents and ex vivo efficacy of different doses of acetylsalicylic acid and ticlopidine in a pulsed floating model of recirculating human plasma. 2002 Dec 1
42 12676188 A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. 2002 Dec 15 2
43 11254909 Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men. 2001 Apr 3
44 11434690 A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. 2001 Jun 1
45 11685164 Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. 2001 Nov 1
46 10735780 The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. 2000 Apr 3
47 10861096 Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. 2000 Jul 1 1
48 10544909 A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). 1999 Oct 2
49 10726037 Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. 1999 Oct 2
50 10726041 Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. 1999 Oct 1